Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-522 in advanced colorectal cancer and solid tumors
NCT00284817Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jul 2001
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etaracizumab in colorectal cancer (CRC), solid tumor, sponsored by MedImmune. Started Jul 2001; status: completed.
02
Drugs
etaracizumab
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT00284817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284817.